Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 5NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1

Conditions

Stomach Neoplasms 2Solid Tumor 1Sarcoma, Clear Cell 1Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × AMG 337 × Clear all
NCT03132155 2024-05-24

QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma

NantPharma, LLC

Phase 2 Terminated
8 enrolled 10 charts
Sarcoma

Sarcoma, Clear Cell

NCT01253707 2022-11-07

A Study of AMG 337 in Subjects With Advanced Solid Tumors

Amgen

Phase 1 Completed
111 enrolled
Tumor-Agnostic

Neoplasms

NCT02096666 2021-12-28

A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects

Amgen

Phase 1/2 Completed
11 enrolled
Gastrointestinal

Stomach Neoplasms

NCT03147976 2019-08-28

QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors

NantPharma, LLC

Phase 2 Withdrawn
Other solid neoplasm

Solid Tumor

NCT02016534 2017-07-02

Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

Amgen

Phase 2 Terminated
60 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡